1. Un-audited Financial Results of the Company for the Quarter and Nine Months Ended December 31, 2025. (Copies enclosed herewith). 2. Took note of Limited Review Report of the Statutory ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs reported weak Q3 FY26 results, with revenue from operations declining about 25% YoY to ₹22.18 crore (vs ₹29.55 crore in Q3 FY25), while net profit was nearly flat at ₹75.76 lakhs vs ₹76.74 lakhs. For the nine months ended December 2025, revenue fell around 17% YoY to ₹72.65 crore and net profit dropped about 20% to ₹2.80 crore (vs ₹3.49 crore). The company reported an exceptional item of ₹25.13 lakhs in the quarter. Separately, the Board approved a short-term working capital term loan of ₹5.50 crore from ICICI Bank for 6 months (bullet repayment) to fund new order execution. The auditor (Ayyadevara & Co.) issued an unqualified Limited Review Report.
The double-digit revenue and profit decline signals demand or pricing pressure that may weigh on the stock, though the new working capital loan points to upcoming order wins. Short-tenure debt with bullet repayment adds a liquidity event to watch at end of term.